In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Pharmaceutical

Division of Endo International PLC
www.parpharm.com/generics.php

Latest From Par Pharmaceutical

Neuraxpharm Names Local Head As It Expands Into UK

Neuraxpharm has appointed Craig Bowen as general manager of its UK affiliate at the same time as the European central nervous system specialist has launched its first products in the UK market.

Strategy Appointments

Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects

The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.

Sales & Earnings Commercial

Cipla Claims Pricing Advantage For Albuterol In US

Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.

Commercial Strategy

Athenex Sues FDA To Get Vasopressin On List Of Drugs That Can Be Compounded

Company argues there is a clinical need for its ready-to-use, preservative-free compounded formulation of vasopressin but agency says Vasostrict is available in a dose without the preservative.

FDA Legal Issues
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register